This Pharmacogenomics test that predicts how patients will respond to cardiac drug therapy based on their individual genetic makeup. Cardiac medicines which are used to prevent:heart attacks , strokes, blood circulation disease, myocardial infarction, blood clots,atrial fibrillation, etc.
Synopsis
This test screens the mutations/variants in the cancers affecting multiple organ systems such as breast, ovarian, uterine colorectal, gastric, pancreatic, thyroid, paraganglioma/ pheochromocytoma, hyperparathyroidism, renal/urinary tract, prostate, melanoma, basal cell nevus syndrome, brain/nervous system tumors, sarcoma and myelodysplastic syndrome/leukemia.
Why to Screen
1. Diagnosis of cancer in early age.
2. A family history of certain type of cancers.
3. Diagnosis of cancer at younger ages in family members.
2. A family history of certain type of cancers.
3. Diagnosis of cancer at younger ages in family members.
Sample Type
Saliva (2 mL) / Blood Sample (3 mL in EDTA Container) / DNA (Extracted from Frozen blood, Buccal swab/scrape, Saliva, Mouthwash (oral rinse), Muscle, skin, or liver tissue, Cultured fibroblasts, Cord blood collected at birth, but not prior to birth)
Genes
ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CASR, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CHEK2, CTNNA1, DICER1, DIS3L2, EGFR, EPCAM, FH, FLCN, GATA2, GPC3, GREM1, HOXB13, HRAS, KIT, MAX, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL4, RET, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERC, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WRN, WT1
No of Genes Screened
83
Limitations
This test screens the coding regions (Exons) and Exon/Inton boundaries upto +/- 10 base pairs in the selected genes that results in hereditary breast, ovarian, uterine, colorectal, gastric, prostate, melanoma, and pancreatic cancers.
Test ID
Test Name
Sample Type
TAT
NMC-PGx01.001
Clopidogrel
Buccal Swab or Blood 3ml (EDTA tube)
3-4 weeks
NMC-PGx01.002
Warfarin & Acenocoumarol (acitrom)
Buccal Swab or Blood 3ml (EDTA tube)
3-4 weeks
NMC-PGx01.003
Statin
Buccal Swab or Blood 3ml (EDTA tube)
3-4 weeks
NMC-PGx01.004
Aspirin
Buccal Swab or Blood 3ml (EDTA tube)
3-4 weeks
NMC-PGx01.005
Ticagelor & parasugel
Buccal Swab or Blood 3ml (EDTA tube)
3-4 weeks
This pharmacogenomics test that predicts how patients will respond to neurology drug therapy based on their individual genetic makeup. Differences between individuals can affect drug absorption, metabolism, or activity. Therefore, while one treatment regimen may work well for one individual, the same regimen may cause adverse effects for other individuals.
Synopsis
This test screens the mutations/variants in the cancers affecting multiple organ systems such as breast, ovarian, uterine colorectal, gastric, pancreatic, thyroid, paraganglioma/ pheochromocytoma, hyperparathyroidism, renal/urinary tract, prostate, melanoma, basal cell nevus syndrome, brain/nervous system tumors, sarcoma and myelodysplastic syndrome/leukemia.
Why to Screen
1. Diagnosis of cancer in early age.
2. A family history of certain type of cancers.
3. Diagnosis of cancer at younger ages in family members.
2. A family history of certain type of cancers.
3. Diagnosis of cancer at younger ages in family members.
Sample Type
Saliva (2 mL) / Blood Sample (3 mL in EDTA Container) / DNA (Extracted from Frozen blood, Buccal swab/scrape, Saliva, Mouthwash (oral rinse), Muscle, skin, or liver tissue, Cultured fibroblasts, Cord blood collected at birth, but not prior to birth)
Genes
ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CASR, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CHEK2, CTNNA1, DICER1, DIS3L2, EGFR, EPCAM, FH, FLCN, GATA2, GPC3, GREM1, HOXB13, HRAS, KIT, MAX, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL4, RET, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERC, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WRN, WT1
No of Genes Screened
83
Limitations
This test screens the coding regions (Exons) and Exon/Inton boundaries upto +/- 10 base pairs in the selected genes that results in hereditary breast, ovarian, uterine, colorectal, gastric, prostate, melanoma, and pancreatic cancers.
Test ID
Test Name
Sample Type
TAT
NMC-PGx02.001
Carbamazepine
Buccal Swab or Blood 3ml (EDTA tube)
3-4 weeks
NMC-PGx02.002
Valproic Acid
Buccal Swab or Blood 3ml (EDTA tube)
3-4 weeks
NMC-PGx02.003
Clobazam
Buccal Swab or Blood 3ml (EDTA tube)
3-4 weeks
NMC-PGx02.004
Clopidogrel
Buccal Swab or Blood 3ml (EDTA tube)
3-4 weeks
NMC-PGx02.005
Aspirin
Buccal Swab or Blood 3ml (EDTA tube)
3-4 weeks
This pharmacogenomics test that predicts how patients will respond to anti-diabetic drug therapy based on their individual genetic makeup. Drug like Metformin helping to restore your body's proper response to the insulin you naturally produce.
Synopsis
This test screens the mutations/variants in the cancers affecting multiple organ systems such as breast, ovarian, uterine colorectal, gastric, pancreatic, thyroid, paraganglioma/ pheochromocytoma, hyperparathyroidism, renal/urinary tract, prostate, melanoma, basal cell nevus syndrome, brain/nervous system tumors, sarcoma and myelodysplastic syndrome/leukemia.
Why to Screen
1. Diagnosis of cancer in early age.
2. A family history of certain type of cancers.
3. Diagnosis of cancer at younger ages in family members.
2. A family history of certain type of cancers.
3. Diagnosis of cancer at younger ages in family members.
Sample Type
Saliva (2 mL) / Blood Sample (3 mL in EDTA Container) / DNA (Extracted from Frozen blood, Buccal swab/scrape, Saliva, Mouthwash (oral rinse), Muscle, skin, or liver tissue, Cultured fibroblasts, Cord blood collected at birth, but not prior to birth)
Genes
ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CASR, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CHEK2, CTNNA1, DICER1, DIS3L2, EGFR, EPCAM, FH, FLCN, GATA2, GPC3, GREM1, HOXB13, HRAS, KIT, MAX, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL4, RET, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERC, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WRN, WT1
No of Genes Screened
83
Limitations
This test screens the coding regions (Exons) and Exon/Inton boundaries upto +/- 10 base pairs in the selected genes that results in hereditary breast, ovarian, uterine, colorectal, gastric, prostate, melanoma, and pancreatic cancers.
Test ID
Test Name
Sample Type
TAT
NMC-PGx03
Antidiabetic Drug(Metformin)
Buccal Swab or Blood 3ml (EDTA tube)
3-4 weeks
This pharmacogenomics test that predicts how patients will respond to immuno-suppressive drug therapy in organ(kidney) transplantation based on their individual genetic makeup. Drug like Tacrolimus, Thiopurines are used mainly after allogeneic organ transplant to lower the risk of organ rejection.
Synopsis
This test screens the mutations/variants in the cancers affecting multiple organ systems such as breast, ovarian, uterine colorectal, gastric, pancreatic, thyroid, paraganglioma/ pheochromocytoma, hyperparathyroidism, renal/urinary tract, prostate, melanoma, basal cell nevus syndrome, brain/nervous system tumors, sarcoma and myelodysplastic syndrome/leukemia.
Why to Screen
1. Diagnosis of cancer in early age.
2. A family history of certain type of cancers.
3. Diagnosis of cancer at younger ages in family members.
2. A family history of certain type of cancers.
3. Diagnosis of cancer at younger ages in family members.
Sample Type
Saliva (2 mL) / Blood Sample (3 mL in EDTA Container) / DNA (Extracted from Frozen blood, Buccal swab/scrape, Saliva, Mouthwash (oral rinse), Muscle, skin, or liver tissue, Cultured fibroblasts, Cord blood collected at birth, but not prior to birth)
Genes
ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CASR, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CHEK2, CTNNA1, DICER1, DIS3L2, EGFR, EPCAM, FH, FLCN, GATA2, GPC3, GREM1, HOXB13, HRAS, KIT, MAX, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL4, RET, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERC, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WRN, WT1
No of Genes Screened
83
Limitations
This test screens the coding regions (Exons) and Exon/Inton boundaries upto +/- 10 base pairs in the selected genes that results in hereditary breast, ovarian, uterine, colorectal, gastric, prostate, melanoma, and pancreatic cancers.
Test ID
Test Name
Sample Type
TAT
NMC-PGx04.001
Tacrolimus
Buccal Swab or Blood 3ml (EDTA tube)
3-4 weeks
NMC-PGx04.002
Thiopurins
Buccal Swab or Blood 3ml (EDTA tube)
3-4 weeks
